NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,419.11 +211.98 (+1.16%) CRUDE OIL
79.20 +0.25 (+0.32%) GOLD FUTURES
2,316.10 +6.50 (+0.28%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,470.66 +1,728.39 (+3.78%)
IMCR May 2024 70.000 call
| Previous close | 1.0900 |
| Open | 1.0900 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 70.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.0900 - 1.0900 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Globe NewswireImmunocore announces upcoming presentation and posters at ASCO 2024
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral abstract session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 24 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to ra
GlobeNewswireImmunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor confere
- GlobeNewswire
Immunocore presented two posters at CROI 2024
Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 05 March 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases,
